Search:

Login | Subscribe

Home > Companies > Evolutec Group

Price	Market	Sector	Market Cap
25.75p (0.00p) 0.00%	AIM	Medicine and Biotech Research	£6.68m

Add to company folder | Print

Related Companies

AGY	10.00p	0.00%
APH	4.62p	0.00%
CBF	2.00p	-11.11%
CRX	2.75p	0.00%
FUL	3.12p	0.00%
FUM	28.25p	-2.59%
GMX	1.75p	0.00%
GWP	30.00p	0.00%
HML	0.42p	0.00%
MMG	7.25p	0.00%
MPM	14.25p	0.00%
OMH	3.50p	0.00%
PLE	16.50p	0.00%
PRM	20.50p	-8.89%
PRX	145.00p	5.46%
RNSM	7.75p	0.00%
RCG	35.00p	-6.67%
RGT	6.50p	0.00%

Commentary

Biopharmaceutical company developing novel products for the treatment of allergic, inflammatory and auto-immune diseases

Recent Articles

Drug floats drying up	02/08/2004
Beesons calls off merger with Evolution	28/09/2001
Start-up brings Dominion to Ofex	14/08/2001
	01/07/2001
EVC Christows	09/02/2001
eVestment/EVC Christows	21/11/2000
eVestment	26/10/2000
eVestment	22/08/2000
eVestment	03/05/2000
eVestment	01/02/2000
More

Recent Announcements

Holding(s) in Company	20/10/2008
Holding(s) in Company	09/09/2008
Holding(s) in Company	01/07/2008
Holding(s) in Company	07/03/2008
Holding(s) in Company	05/03/2008
Holding(s) in Company	30/01/2008
Holding(s) in Company	06/12/2007
Holding(s) in Company	23/11/2007
Holding(s) in Company	13/11/2007
Holding(s) in Company	30/10/2007
More

Articles from the Sector

Stroke hope at ReNeuron	28/11/2008
Futura Medical	28/11/2008
Option deal boosts ImmuPharma	25/11/2008
Digital imager targets AIM	24/11/2008
Vectura loses interim £11.7m	24/11/2008
GW trims loss	19/11/2008
Asterand	18/11/2008
EU trial cheers Plethora	07/11/2008
IS Pharma	05/11/2008
Animalcare nurturing high-margin growth	03/11/2008
More

Financial History

Financial Year End	31/12/2003	31/12/2004	31/12/2005	31/12/2006	31/12/2007
Currency	GBP	GBP	GBP	GBP	GBP
Turnover	0.00	0.03	0.01	0.01	0.08
Operating Profit	-1.11	-2.51	-7.00	-12.86	-2.29
Pretax Profit	-1.09	-2.41	-6.13	-12.47	-1.92
Earnings After Tax	-1.00	-2.24	-5.61	-11.83	-1.76
Profit Available For Dividend	0.00	0.00	0.00	0.00	0.00
Ordinary Dividends	0.00	0.00	0.00	0.00	0.00
Retained Profit	-1.00	0.00	0.00	0.00	0.00
Shareholders Funds	0.23	3.77	17.18	8.28	5.95
Net Current Assets	0.22	3.76	0.00	0.00	0.00
Adjusted Earnings Per Share Undiluted	0.00	0.00	-34.80	-49.30	-6.80
Adj Earnings Per Share	0.00	0.00	-34.80	-49.30	-6.80
Dividend Per Share	0.00	0.00	0.00	0.00	0.00

Chart

Click here for interactive charting

Company Details
Address	3 More London Riverside, London, SE1 2AQ
Telephone
Fax
Executives
Chairman	David Bloxham (0.50% holding)
Chief Executive	(0.00% holding)
Finance Director	(0.00% holding)
Non-Exec Director	Graeme Hart (0.90% holding)
Main Shareholders
	Gartmore: 14.5% Bluehone Investors: 12.2% Deutsche Bank: 11.3% Cantor Fitzgerald Europe: 11.1%
Advisers
Nominated Adviser	Numis
Nominated Broker	Numis
Solicitors	Norton Rose
Auditors	Grant Thornton
Registrar	Capita Registrars

Commentary
Biopharmaceutical company developing novel products for the treatment of allergic, inflammatory and auto-immune diseases
Company Data
Code	EVC
Sedol	GB00B01JLR
Shares In Issue	25.950 m
Indices
Entry on AIM	02/08/2004
Interim Results	Sep
Final Results	Mar
Year End	Dec
Accounts Due	Oct
Int div payment	n/a
Fin div payment	n/a
Int net div per share	nil
Fin net div per share	nil
Probable CGT relief	Yes